EMPAGLIFLOZIN AND LINAGLIPTIN (empagliflozin; linagliptin) by Prinston Inc is contains: empagliflozin, a sglt2 inhibitor, and linagliptin, a dpp-4 inhibitor. Approved for cardiovascular (cv) death in adults with type 2 diabetes mellitus, established cv disease [see ], established cv disease and 2 more indications.
Drug data last refreshed 13h ago
contains: empagliflozin, a SGLT2 inhibitor, and linagliptin, a DPP-4 inhibitor. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin…
Worked on EMPAGLIFLOZIN AND LINAGLIPTIN at Prinston Inc? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes